title: [Splenic marginal zone lymphoma associated with autoimmune hemolytic anemia treated with splenectomy and rituximab].
abstract: A 51-year-old woman, who presented with dyspnea on effort and was diagnosed with autoimmune hemolytic anemia in July 2004, was suspected of having splenic marginal zone lymphoma (SMZL) because of clonality of B cell on bone marrow and splenomegaly. She underwent splenectomy, and histopathological examination of the resected specimen confirmed the diagnosis of SMZL. The patient was treated with rituximab, and complete remission was achieved. Up to the present, three years after diagnosis, the patient has shown no evidence of progression.
authors: Department of Internal Medicine, Yamada Red Cross Hospital.
authors: Minoru
authors: M
authors: Miztani
authors: Tomohiro
authors: T
authors: Noda
authors: Akira
authors: A
authors: Umino
authors: Motoaki
authors: M
authors: Tanigawa
authors: Masanori
authors: M
authors: Taniguchi
authors: Shigehisa
authors: S
authors: Tamaki
authors: Kouta
authors: K
authors: Tsuji
mesh_terms: D000744:Anemia, Hemolytic, Autoimmune / Q000628:therapy*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D000069283:Rituximab; D013156:Splenectomy; D013160:Splenic Neoplasms / Q000473:pathology / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab